Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 21 EP applications Ana Esther Gabarda Ortega has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 15, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11785381

SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS

IPC classification:
A61K 31/192, A61K 31/216, A61K 31/341, A61K 31/40, A61K 31/437, A61K 31/4402, A61P 9/08, C07C 235/36, C07C 235/40, C07D 207/16, C07D 213/55, C07D 235/00, C07D 257/04, C07D 307/52
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11790902

SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS

IPC classification:
A61K 31/192, A61K 31/216, A61P 9/08, C07C 235/70
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12710792

TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS

IPC classification:
A61K 31/444, A61P 35/00, C07D 213/81, C07D 401/14, C07D 405/14, C07D 417/12, C07D 417/14
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12709966

NOVEL KINASE INHIBITORS

IPC classification:
A61K 31/444, A61P 35/00, A61P 37/00, C07D 213/75, C07D 401/14, C07D 405/14, C07D 409/14, C07D 413/14
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12713354

COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE

IPC classification:
A61K 31/44, A61K 31/4748, A61K 45/06, A61P 25/16
Applicant:
Novartis AG
Agent:
Appleyard Lees Ltd
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12735521

SALTS OF AZA-BICYCLIC DI-ARYL ETHERS AND METHODS TO MAKE THEM OR THEIR PRECURSORS

IPC classification:
A61K 31/439, A61P 25/16, A61P 25/18, A61P 25/22, A61P 25/24, A61P 25/28, C07D 453/02
Applicant:
Novartis AG
Agent:
Jennifer Delaney, Appleyard Lees Ltd
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
PATENT GRANTED
EP12795066

CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS

IPC classification:
A61K 31/496, A61P 25/00, C07D 211/46, C07D 401/04, C07D 401/14, C07D 417/04, C07D 417/14, C07D 487/04
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
PATENT GRANTED
EP14155848

Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors

IPC classification:
A61K 31/41, A61K 31/415, A61K 31/42, A61P 7/10, C07D 231/40, C07D 257/06, C07D 261/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP13770709

CARBAMATE/UREA DERIVATIVES

IPC classification:
A61K 31/4545, A61P 25/00, C07D 401/04, C07D 401/14
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13783671

DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE

IPC classification:
A61K 31/551, A61P 1/04, A61P 25/16, A61P 25/28, C07D 471/04
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14707887

SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS

IPC classification:
A61K 31/66, A61P 9/00, A61P 25/00, C07F 9/38
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14707056

SUBSTITUTED BISPHENYL BUTANOIC ACID DERIVATIVES AS NEP INHIBITORS WITH IMPROVED IN VIVO EFFICACY

IPC classification:
A61K 31/4245, A61P 9/00, A61P 11/00, A61P 13/00, A61P 25/00, A61P 29/00, C07D 271/113
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11784638

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

IPC classification:
A61K 31/192, A61K 31/194, A61K 31/197, A61K 31/198, A61K 31/216, A61K 31/235, A61K 31/265, A61K 31/335, A61K 31/34, A61K 31/35, A61K 31/381, A61K 31/40, A61K 31/41, A61K 31/42, A61K 31/44, A61K 31/505, A61K 31/513, A61K 31/5375, A61K 31/55, A61K 45/06, A61P 13/12
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14766806

AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE

IPC classification:
A61K 31/41, A61K 31/4245, A61K 31/427, A61K 31/4439, A61K 31/497, A61K 31/506, A61K 31/5377, A61K 31/5513, C07D 401/10, C07D 401/12, C07D 401/14, C07D 403/10, C07D 403/12, C07D 403/14, C07D 413/14
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14766209

AUTOTAXIN INHIBITORS

IPC classification:
A61K 31/41, A61P 35/00, C07D 257/04, C07D 401/12, C07D 403/12, C07D 405/12, C07D 413/12, C07D 417/12
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14792587

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

IPC classification:
A61K 31/437, A61P 35/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP16154129

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

IPC classification:
A61K 31/194, C07C 235/52, C07C 271/12, C07C 275/16, C07C 311/19, C07C 317/44, C07D 213/81, C07D 213/82, C07D 231/14, C07D 239/28, C07D 257/06, C07D 261/18, C07D 309/40, C07D 333/24, C07D 333/40
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13151792

Substituted aminopropionic derivatives as neprilysin inhibitors

IPC classification:
A61K 31/21, A61K 31/435, C07C 233/47, C07D 213/82, C07D 239/36, C07D 261/18, C07D 271/06
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP13151795

Substituted aminopropionic derivatives as neprilysin inhibitors

IPC classification:
A61K 31/21, A61K 31/435, C07C 233/47, C07D 213/82, C07D 239/36, C07D 261/18, C07D 271/06
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP15720471

AUTOTAXIN INHIBITORS

IPC classification:
A61K 31/445, A61K 31/4468, A61K 31/454, A61P 3/00, A61P 11/00, A61P 29/00, A61P 35/00, C07D 211/26, C07D 211/34, C07D 211/58, C07D 249/04, C07D 263/38, C07D 265/30, C07D 401/06, C07D 401/12, C07D 403/12, C07D 413/12, C07D 417/12, C07D 451/04
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16701202

PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS

IPC classification:
A61K 31/40, A61P 25/00, A61P 29/00, A61P 35/00, C07D 403/04, C07D 413/04, C07D 417/04, C07D 471/04, C07D 495/04
Applicant:
Novartis AG
Agent:
Ana Esther Gabarda Ortega, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature